复方川芎胶囊联合阿罗洛尔治疗心绞痛的临床研究

目的 探讨复方川芎胶囊联合盐酸阿罗洛尔片治疗心绞痛的临床疗效.方法 选择2020年6月—2021年6月在濮阳市油田总医院治疗的118例心绞痛患者,根据用药的差别分为对照组和治疗组,每组各59例.对照组口服盐酸阿罗洛尔片,10 mg/次,1次/d;治疗组在对照组基础上口服复方川芎胶囊,4粒/次,3次/d.两组均经8周治疗...     

通心络胶囊联合曲美他嗪治疗冠心病心绞痛的临床观察

目的:考查通心络胶囊联合曲美他嗪治疗冠心病心绞痛的临床疗效.方法:选取本院2019年1月—2020年6月就诊的90例冠心病心绞痛患者,分为对照组和观察组各45例,两组患者均依据患者情况对症给予降压药物、降脂药物和降血小板药物等常规治疗,在此基础上对照组口服曲美他嗪片,20 mg/次,3次/d;观察组在对照组基础上加用通...     

通心络胶囊治疗老年冠心病心绞痛184例观察

目的观察通心络胶囊治疗冠心病心绞痛的疗效。方法冠心病患者344例随机分成两组,治疗组184例以通心络胶囊4粒,3次/d,口服;对照组160例以单硝酸异山梨脂20mg,3次/d,口服。平均疗程均为4周。观察治疗前后冠心病心绞痛改善情况。结果心绞痛改善总有效率治疗组为91.76%,对照组为46.16%,(P<0.01);心电图改善总有效率治疗组为60.16%,对照组为32.63%(P<0.05)。结论通心络胶囊对冠心病心绞痛的治疗效果明显优于单硝酸异山梨脂。     

参松养心胶囊联合单硝酸异山梨酯治疗冠心病心绞痛的疗效观察

目的研究参松养心胶囊联合单硝酸异山梨酯片治疗冠心病心绞痛的临床疗效。方法选取2015年6月—2017年6月新疆维吾尔自治区人民医院收治的冠心病心绞痛患者120例作为研究对象,将所有患者随机分为对照组和治疗组,每组各60例。对照组患者口服单硝酸异山梨酯片,1片/次,2次/d。治疗组在对照组治疗的基础上口服参松养心胶囊,3粒/次,3次/d。两组患者持续治疗28 d。观察两组的临床疗效和心电图疗效,比较两组的临床症状。结果治疗后,对照组和治疗组的临床总有效率分别为85.00%、96.67%,两组比较差异有统计学意义(P0.05)。治疗后,对照组和治疗组的心电图疗效有效率分别为80.00%、95.00%,两组比较差异有统计学意义(P0.05)。治疗后,两组心绞痛发作次数和心绞痛持续时间均显著降低,同组治疗前后比较差异有统计学意义(P0.05);且治疗组临床症状明显低于对照组,两组比较差异具有统计学意义(P0.05)。结论参松养心胶囊联合单硝酸异山梨酯片治疗冠心病心绞痛具有较好的临床疗效,可改善患者临床症状,安全性较好,具有一定的临床推广应用价值。     

麝香保心丸联合替格瑞洛治疗冠心病心绞痛的临床研究

目的 探究麝香保心丸联合替格瑞洛片治疗冠心病心绞痛的临床疗效.方法 选择2019年11月—2021年2月在济源市人民医院就诊治疗的102例冠心病心绞痛患者,按照入院先后顺序将所有患者分为对照组和治疗组,每组各51例.对照组口服替格瑞洛片,90 mg/次,2次/d.治疗组在对照组的基础上口服麝香保心丸,45 mg/次,3...     

冠脉通片联合氯吡格雷治疗冠心病心绞痛的临床研究

目的 探讨冠脉通片联合硫酸氢氯吡格雷片治疗冠心病心绞痛的临床疗效.方法 选取2019年5月—2020年5月在天津市南开区中医医院治疗的冠心病心绞痛患者94例,根据就诊顺序分为对照组(47例)和治疗组(47例).对照组口服硫酸氢氯吡格雷片,75 mg/次,1次/d;治疗组在对照组的基础上口服冠脉通片,1.8 g/次,3次...     

银杏叶滴丸联合非洛地平治疗冠心病心绞痛的临床研究

目的探讨银杏叶滴丸联合非洛地平治疗冠心病心绞痛的有效性与安全性。方法选取滨州医学院烟台附属医院2015年12月—2017年6月收治的冠心病心绞痛患者146例,根据治疗方案的不同分成对照组(73例)和治疗组(73例)。对照组患者口服非洛地平缓释片,1片/次,1次/d。治疗组患者在对照组的基础上口服银杏叶滴丸,5丸/次,3次/d。所有患者均治疗2个月。观察两组患者临床疗效,比较治疗前后两组患者心绞痛发作频率和平均持续时间,运动耐力、血清P选择素水平、生活质量评分、心脏指标和舒张期冠状动脉血流峰值速度及不良反应情况。结果治疗后,对照组临床总有效率为84.93%,显著低于治疗组的95.89%,两组比较差异具有统计学意义(P0.05)。治疗后,两组患者心绞痛发作频率和平均持续时间均显著降低(P0.05);且治疗组患者发作频率和平均持续时间明显低于对照组患者(P0.05)。治疗后,两组患者6 min步行距离和生活质量评分均显著增加(P0.05),血清P选择素水平显著降低(P0.05);且治疗后治疗组上述指标明显优于对照组(P0.05)。治疗后,两组患者LVEF和舒张期冠状动脉血流峰值速度显著升高(P0.05),LVEDD显著降低(P0.05);且治疗组患者这些指标治疗后水平明显优于对照组(P0.05)。治疗组不良反应发生率为2.74%,明显低于对照组的13.70%,两组比较差异具有统计学意义(P0.05)。结论银杏叶滴丸联合非洛地平治疗冠心病心绞痛疗效显著,不良反应发生率低,具有一定的临床推广应用价值。     

脉君安片联合缬沙坦治疗中老年原发性高血压的临床研究

目的 探讨脉君安片联合缬沙坦胶囊治疗中老年原发性高血压的临床疗效.方法 选择2021年2月—2021年6月在天津市红桥医院治疗的102例原发性高血压老年患者,根据用药的差别分为对照组和治疗组,每组各51例.对照组口服缬沙坦胶囊,80 mg/次,1次/d;治疗组在对照组基础上口服脉君安片,1.5 g/次.3次/d.两组患...     

心脑欣胶囊治疗心绞痛病人的疗效

目的：观察心脑欣胶囊治疗冠心病心绞痛的临床疗效。方法：136例确诊为冠心病心绞痛的病人入选，并随机分为观察组与对照组。观察组101例，口服心脑欣胶囊，2次／d，2粒／次；对照组35例，口服诺迪康胶囊，3次／d，1粒／次。服药时间为4周。观察服药期间心绞痛治疗效果及可能的不良反应。结果：两组病人每周心绞痛发作次数显著减少，心绞痛发作持续时间明显缩短。观察组显效率为39．6％，总有效率达91．1％；对照组显效率与总有效率分别为40．0％与85．7％。所有病人服药期间均未出现不良反应。结论：心脑欣胶囊治疗冠心病心绞痛效果确切、服用安全。     

心脑联通胶囊治疗冠心病心绞痛的临床研究

目的观察心脑联通胶囊治疗冠心病心绞痛的疗效及安全性。方法采用随机对照方法，治疗组与对照组均予常规治疗、休息，同时予鲁南欣康20mg，倍他乐克25mg，2次/d口服。治疗组在常规治疗的同时给予心脑联通胶囊1.0g，3次/d口服。两组疗程均为20d。结果在心绞痛缓解、心绞痛发作次数减少与发作时间缩短、心电图、心功能、血液流变及血脂等指标的改善方面，治疗组均优与对照组。治疗组总有效率96.08%，与对照组79.16%比较，差异有统计学意义（P〈0.01）。结论心脑联通胶囊治疗冠心病、心绞痛疗效迅速确切，无明显不良反映。     

The effect of quinidine on the analgesic effect of codeine

Summary We have studied the hypoalgesic effect of codeine (100 mg) after blocking the hepatic O-demethylation of codeine to morphine via the sparteine oxygenase (CYP2D6) by quinidine (200 mg). The study was performed in 16 extensive metabolizers of sparteine, using a double-blind, randomized, four-way, cross-over design. The treatments given at 3 h intervals during the four sessions were placebo/placebo, quinidine/placebo, placebo/codeine, and quinidine/codeine. We measured pin-prick pain and pain tolerance thresholds to high energy argon laser stimuli before and 1, 2, and 3 h after codeine or placebo.After codeine and placebo, the peak plasma concentration of morphine was 6–62 (median 18) nmol·.l^–1. When quinidine pre-treatment was given, no morphine could be detected (<4 nmol·l^–1) after codeine. The pin-prick pain thresholds were significantly increased after placebo/codeine, but not after quinidine/codeine compared with placebo/placebo. Both placebo/codeine and quinidine/codeine increased pain tolerance thresholds significantly. Quinidine/codeine and quinidine/placebo did not differ significantly for either pin-prick or tolerance pain thresholds.These results are compatible with local CYP2D6 mediated formation of morphine in the brain, not being blocked by quinidine. Alternatively, a hypoalgesic effect of quinidine might have confounded the results.     

罗森塔尔效应在急诊带教中的应用效果分析

目的分析罗森塔尔效应在急诊带教中的应用效果。方法选取我院2015年7~2016年4月期间的急诊实习学生共61例,按照双盲法分为观察组(n=31)和参照组(n=30),参照组实习学生应用常规带教教学方式,观察组实习学生应用罗森塔尔效应带教教学方式,对比分析两组实习学生的考核成绩和护理满意评分。结果在考核成绩对比中,经一段时间学习后,观察组实习学生无论是理论成绩还是实践成绩均优于参照组,差异有统计学意义(P<0.05);在护理满意评分对比中,观察组实习学生在学习主动性、学习能力、专业技能、自律性及总分等护理满意评分中均高于参照组,差异有统计学意义(P<0.05)。结论急诊带教中应用罗森塔尔效应的效果显著,能够提高学生学习自主性、专业知识掌握程度和专业技能,具有较高的实践应用价值,有利于学生更快更好的适应急诊病房环境。     

罗格列酮的胰岛素增敏作用和胰岛素抵抗改善作用

目的　观察罗格列酮的胰岛素增敏作用和胰岛素抵抗改善作用。方法　大鼠尾静脉注射链佐菌素 (5 0mg·kg-1)制备IDDM模型 ,观察单用罗格列酮、单用小剂量胰岛素 (皮下注射 2 5U·鼠 -1)、罗格列酮并用小剂量胰岛素的降糖作用 ;大鼠尾静脉注射卡介苗 (10mg·鼠 -1)制备免疫性胰岛素抵抗模型 ,观察罗格列酮对模型的葡萄糖输注速率的回升作用。结果　罗格列酮 1,3 ,10 μmol·kg-13个剂量组连续灌胃给药 8d ,均未能降低正常大鼠血糖 ,也未能降低链佐菌素所致糖尿病大鼠血糖 ;但在并用小剂量胰岛素条件下 ,罗格列酮 3 ,10 μmol·kg-1连续灌胃给药 8d ,能降低链佐菌素所致糖尿病大鼠血糖 ;罗格列酮 10 μmol·kg-1连续灌胃给药 8d后 ,用正糖钳技术检测 ,免疫性胰岛素抵抗模型亚极高和极高胰岛素状态下的葡萄糖输注速率均得到回升。结论　罗格列酮具有胰岛素增敏作用和胰岛素抵抗改善作用     

The effect of carbon disulphide on the stereotypic effect of dopamine agonists

Exposure to CS₂ increased the intensityof apomorphine-induced stereotypy in male rats without increasing the reaction time. With amphetamine, an indirect agonist of dopamine, exposure to CS₂ had a more intensive effect and significantly prolonged the length of reaction.     

黄谷素抗心律失常作用及其机制

黄谷素能明显对抗大鼠乌头碱、冠脉结扎诱发的心律失常；对乌头碱引起犬的心律失常有明显治疗作用。在膜片钳实验中发现，黄谷素能显著抑制豚鼠左房单细胞延迟外向钾电流和尾电流，这一作用具有浓度依赖性。黄谷素１０μｍｏｌ·Ｌ－１使ＩＫ从给药前的１１６０ｐＡ减少到８１０ｐＡ，使尾电流从给药前的３３１ｐＡ减少到１９６ｐＡ，此作用在膜电位０～６０ｍＶ区间作用较强。黄谷素抑制延迟外向钾电流和尾电流是其抗心律失常作用机制。     

Pressor effect of indolethylamines

6-Hydroxytryptamine, 7-hydroxytryptamine and 5,7-dihydroxytryptamine increase blood pressure when given intravenously to pithed rats and effect not due to stimulation of 5-hydroxytryptamine receptors. 6-Hydroxytryptamine and 7-hydroxytryptamine interact with α-adrenoceptors of the vascular bed. An effect of 5,7-dihydroxytryptamine on α-adrenoceptors was not established.     

Vasorelaxant effect of harman

The in vivo cardiovascular effect and in vitro vasorelaxant effect of harman, one of harmala alkaloids isolated from Peganum harmala, were examined in this study. Harman (1-10 mg/kg, i.v.) dose-dependently produced transient hypotension and long-lasting bradycardia in pentobarbital-anesthetized rats, which were attenuated by N(G)-nitro-L-arginine pretreatment. In isolated rat endothelium-intact thoracic aortic rings, harman concentration dependently relaxed phenylepherine-induced contractions with an IC(50) value around 9 microM. This vasorelaxant effect was attenuated by endothelium removal or N(omega)-nitro-L-arginine methyl ester pretreatment, but not by tetraethylammonium or indomethacin pretreatment. In cultured rat aortic endothelial cells, harman (1-100 microM) concentration dependently increased nitric oxide (NO) release, which was dependent on the presence of external Ca(2+). Harman pretreatment (3-30 microM) also concentration dependently inhibited the contractions induced by phenylephrine, 5-hydroxytryptamine (5-HT), and KCl in endothelium-denuded aortic rings in a non-competitive manner. In addition, harman pretreatment reduced both phasic and tonic phases of phenylephrine-induced contractions. Receptor binding assays further indicated that harman (K(i) values around 5-141 microM) interacted with the cardiac alpha(1)-adrenoceptors, brain 5-HT(2) receptors, and cardiac 1, 4-dihydropyridine binding site of L-type Ca(2+) channels. Therefore, the present results suggested that the vasorelaxant effect of harman was attributed to its actions on the endothelial cells to release NO and on the vascular smooth muscles to inhibit the contractions induced by the activation of receptor-linked and voltage-dependent Ca(2+) channels. The vasorelaxant effect may be involved in the hypotensive effect of harman.     

Post-antibacterial effect of thymol

The antibacterial activity of thymol has been well established and reported in the scientific literature. Continued suppression of bacterial growth following limited exposure to antimicrobial compounds at different concentrations greater than or equal to the minimum inhibitory concentration level (MIC) and at concentrations less than the MIC can be used as an indicator of biological activity, and are respectively referred to as a post-antibacterial effect (PAE) and a post-antibiotic sub-MIC effect (PA-SME). In this study, the PAE and the PA-SME of thymol against Escherichia coli, Staphylococcus aureus, Pseudomonas aeruginosa, and Bacillus cereus were investigated. A spectrophotometric method was used to determine the PAE and the PA-SME of thymol against the selected test strains. Thymol exhibited a considerable PAE and PA-SME at MIC and sub-MIC concentrations against test strains. The greatest duration of both the PAE and the PA-SME was observed for thymol against E. coli and P. aeruginosa. The PAE and PA-SME times for E. coli were 12 and 8?h, respectively, and for P. aeruginosa were 11 and 7.5?h, respectively. The duration of the PAE and PA-SME observed for S. aureus and B. cereus was shorter than for Gram-negative strains.     

Anti-arrhythmic effect of oxyfedrin

Oxyfedrin, L-3-methoxy-(l-hydroxy-l-phenylisopropylamino)-propiophenone hydrochloride, displays in rats and dogs a pronounced anti-arrhythmic effect against spontaneous and drug-induced arrhythmias (ouabain, barium chloride, aconitine). Doses of 1 mg/kg, given intramuscularly (i.m.) or intravenously (i.v.) offered protection against chloroform-adrenaline-induced ventricular fibrillation. The mechanisms possibly involved in the anti-arrhythmic activity of oxyfedrine are discussed.     

阿西莫司的降脂效应

高脂血症Ⅱ_b型患者30例(男、女各15例,年龄60±s 10a)采用口服阿西莫司胶囊250mg,tid×2mo治疗。结果:总胆固醇、甘油三酯、低密度脂蛋白胆固醇、脂蛋白(a)均显著下降(P<0.05),而高密度脂蛋白胆固醇及载脂蛋白A与B的比值显著升高(P<0.05)。无明显不良反应。对血糖,血尿酸,肝、肾功能均无影响。适用于治疗Ⅱ_b型高脂血症。